Brand-name drug · GLP-1 receptor agonist
Saxenda (liraglutide)
From the FDA label, read Published by PepVault
Saxenda is Novo Nordisk’s daily liraglutide injection for weight.
FDA approved it, with a reduced-calorie diet and more activity, to reduce excess weight and keep it off in adults with obesity or with overweight and a weight-related condition, and in children 12 and older with obesity who weigh more than 60 kg.
- Active ingredient
- Liraglutide
- Maker
- Novo Nordisk
- Class
- GLP-1 receptor agonist
- FDA application
- NDA 206321, first approved 2014
What FDA approved it for
It is the same molecule as Victoza at a higher daily dose. The label advises against pairing Saxenda with another liraglutide product or any GLP-1 medicine, and notes its safety in children with type 2 diabetes has not been established.
From the label: 2.1 Important Administration Instructions; 1 Indications and Usage.
How it is supplied
| Form | Doses |
|---|---|
| Prefilled pen (3 mL) | 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3 mg (doses it delivers) |
From the label: 3 Dosage Forms and Strengths.
The label’s dosing schedule
This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.
Saxenda, once a day
| Dose | When, on the label |
|---|---|
| 0.6 mg a day | Week 1 |
| 1.2 mg a day | Week 2 |
| 1.8 mg a day | Week 3 |
| 2.4 mg a day | Week 4 |
| 3 mg a day | Week 5 onward (maintenance) |
For adults the lasting dose is 3 mg a day; the lower doses exist only to climb. An adult who can’t tolerate 3 mg stops Saxenda, while a child may stay at 2.4 mg.
A step that is hard to tolerate can wait about one more week, and in children the climb may take up to 8 weeks.
From the label: 2.2 Dosage in Adults and Pediatric Patients Aged 12 Years and Older.
How it’s taken
A single daily shot, at any hour and whether or not food has been eaten, into the abdomen, thigh or upper arm, rotating within one area. The label wants training on the injection before the first dose.
Saxenda has a built-in check: if an adult hasn’t lost at least 4% of their starting weight 16 weeks in, the label says to stop, because lasting results are unlikely. For children the check is a BMI drop of at least 1% after 12 weeks on the full dose.
From the label: 2.1 Important Administration Instructions; 2.2 Dosage in Adults and Pediatric Patients Aged 12 Years and Older.

If a dose is missed
If a day is missed, the label goes on with the next scheduled dose and never doubles up.
A gap of more than 3 days sends the dose back to 0.6 mg and the climb starts again.
From the label: 2.1 Important Administration Instructions.
Storage
Unused pens are refrigerated at 36°F to 46°F and never frozen. After the first injection, a pen keeps 30 days at 59°F to 86°F or in the fridge; heat and sunlight are to be avoided.
From the label: 16 How Supplied/Storage and Handling.
Side effects and warnings
| Reaction | Placebo | Saxenda |
|---|---|---|
| Nausea | 13.8 | 39.3 |
| Diarrhea | 9.9 | 20.9 |
| Constipation | 8.5 | 19.4 |
| Vomiting | 3.9 | 15.7 |
| Injection site reaction | 10.5 | 13.9 |
| Headache | 12.6 | 13.6 |
| Low blood sugar (in type 2 diabetes) | 6.6 | 12.6 |
| Dyspepsia | 2.7 | 9.6 |
| Fatigue | 4.6 | 7.5 |
| Dizziness | 5 | 6.9 |
The boxed warning
The other warnings
It also warns about pancreatitis, gallbladder disease, low blood sugar, a raised heart rate, kidney injury from dehydration, severe stomach effects, allergic reactions and aspiration during anesthesia.
From the label: 6.1 Clinical Trials Experience; Boxed Warning; 5 Warnings and Precautions.
How Saxenda differs from Victoza
Saxenda and Victoza hold the same active ingredient, liraglutide. What sets them apart is on their labels: what each is approved for, the forms it comes in and how high its schedule goes.
| Compared | Saxenda | Victoza |
|---|---|---|
| Approved for | Weight reduction (adults and children 12 and up) | Type 2 diabetes (adults and children 10 and up); heart risk |
| Forms | Prefilled pen | Prefilled pen |
| Label’s dose range | 0.6 mg to 3 mg once a day | 0.6 mg to 1.8 mg once a day |
| Top dose | 3 mg a day | 1.8 mg a day |
| Maker | Novo Nordisk | Novo Nordisk |
What else we have on liraglutide
Liraglutide on PepVault
The trials, in plain English
Brand against brand
Compound against compound
Questions about Saxenda
What is the Saxenda dosing schedule?
The label raises the daily dose each week: 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, then 3 mg a day from week 5. A prescriber sets the actual schedule.
When should Saxenda be stopped?
The label says to stop if an adult has not lost at least 4% of their starting weight after 16 weeks, or cannot tolerate the 3 mg dose.
What if I miss a Saxenda dose?
Carry on with the next scheduled dose and don’t take extra. After more than 3 days without it, the label restarts at 0.6 mg a day.
Is Saxenda the same as Victoza?
Both are liraglutide from Novo Nordisk. Saxenda is approved for weight at up to 3 mg a day; Victoza is approved for type 2 diabetes at up to 1.8 mg a day.
Sources
- SAXENDA (liraglutide) injection, for subcutaneous use, FDA label on DailyMed (version 22, published Jun 15, 2026; read Nov 18, 2026)
- Drugs@FDA, NDA 206321 (Saxenda, the injection; application first approved 2014)
PepVault is not affiliated with Novo Nordisk. Saxenda is a trademark of its owner.